Skip to main content

Drug Interactions between cyclosporine ophthalmic and Ocupress

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

carteolol ophthalmic cycloSPORINE ophthalmic

Applies to: Ocupress (carteolol ophthalmic) and cyclosporine ophthalmic

MONITOR: There is limited experience with the concomitant use of cyclosporine eye drops with beta-blocker containing eye drops in people with glaucoma. Eye drops containing beta-blockers may have effects in reducing tear secretion, which counteract the effect of cyclosporine eye drops in increase tear production and may increase intraocular pressure. Clinical data are unavailable.

MANAGEMENT: Caution and regular clinical monitoring are recommended if cyclosporine-containing eye drops are used in people with glaucoma, particularly those treated with eye drops containing beta blockers.

References

  1. (2022) "Product Information. Restasis (cycloSPORINE ophthalmic)." Allergan Inc
  2. Cerner Multum, Inc. "UK Summary of Product Characteristics."
  3. Cerner Multum, Inc. "Australian Product Information."

Switch to consumer interaction data

Drug and food interactions

No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer